P
ALNY icon

&Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

&Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$955K Sell
3,203
-27
-0.8% -$8.14K ﹤0.01% 1445
2026
Q1 		$1.07M Buy
3,230
+533
+20% +$181K 0.01% 1262
2025
Q4 		$1.07M Sell
2,697
-46
-2% -$20.4K 0.01% 1180
2025
Q3 		$1.25M Buy
2,743
+1,213
+79% +$494K 0.01% 979
2025
Q2 		$498K Buy
1,530
+702
+85% +$194K ﹤0.01% 1363
2025
Q1 		$223K Buy
+828
New +$213K ﹤0.01% 1571

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

&Partners's ALNY Position: Q2 2026 in Review

&Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.84% in Q2 2026, selling an estimated $8.14K and leaving 3,203 shares worth $955K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

&Partners first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.25M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • &Partners held 3,203 shares of Alnylam Pharmaceuticals worth $955K as of Q2 2026.
  • &Partners sold 27 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $8.14K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1445 holding.
  • &Partners first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • &Partners's Alnylam Pharmaceuticals position peaked at $1.25M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.